🎥 Opportunity in a Beaten-Down Pharma Stock?

It may have hit bottom... ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Note: Is edwardlorilla1986.paxforex@blogger.com your correct email? You haven't clicked in a while and we're concerned you might lose access. Please confirm your address with one click here. Stock of the Week: Opportunity in a Beaten-Down Pharma Player? SPONSORED The New King of Electric Vehicles You probably haven't heard about this revolutionary car. Or the little-known company behind it. Yet it could soon become the new king of the EV industry. >> See the details HERE << Alpesh Patel Trading Champion Healthcare is one of the few industries that is sure to grow for years to come. It's not like we're going to stop spending on our health. But knowing which companies will be part of that growth is far trickier to figure out. That's where my proprietary GVI algorithm comes in. And this week, I've set its sights on a reader-requested stock. [Alexander Green Reveals Where He's Going "All-In" Right Now. Click Here to Find Out.] This multinational biopharma company has strong annual earnings growth. But we also need to look at revenue and profits... and there are a few red flags. So should investors steer clear of this stock... or is there a glimmer of hope for future returns? Get all the details in this week's Stock of the Week. Click here or on the image below to watch it. Show Me the Stock Happy hunting, Alpesh P.S. Send the stocks you'd like me to analyze in a note to mailbag@manwardpress.com. I'll be sure to cover them in future videos. SPONSORED Bombshell opportunity: "America's Next Big Monopoly" A little-known company is making all the right moves to destroy the competition in today's hottest industry. The media is already comparing it to the biggest success stories of our times. While Forbes says this company could be the next Apple or Microsoft, Barron's says this could be the "next big thing." Bill Gates has already invested millions into this company. So has tech investor Cathie Wood. If you're looking for massive gains... this could well be the biggest opportunity of your lifetime.   Want more content like this? YES NO   Alpesh Patel | Trading Champion Alpesh Patel is an award-winning hedge fund and private equity fund manager, international bestselling author, and entrepreneur. He is the founder and CEO of Praefinium Partners, a Financial Times top FTSE 100 forecaster, and a senior Dealmaker in the U.K.'s Department for International Trade. As a recognized authority on fintech, online trading and venture capital, his past and current client list includes American Express, Merrill Lynch HSBC, Charles Schwab, Goldman Sachs, Barclays... and more.   Was this email forwarded to you? Click here to sign up! You are receiving this email because you subscribed to Manward Financial Digest. To unsubscribe from Manward Financial Digest, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press, LLC | Attn: Support Team | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website | Privacy Policy Keep the emails you value from falling into your spam folder. Whitelist Manward Financial Digest. © 2023 Manward Press, LLC | All Rights Reserved Nothing published by Manward Press should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed personalized investment advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after publication before trading on a recommendation. Any investments recommended by Manward Press should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, LLC, 14 West Mount Vernon Place, Baltimore, MD 21201.